SmartTab Completes Successful Preclinical Animal Studies for TargetTab™ Platform
SmartTab is pioneering a wireless remote controlled drug delivery system, has completed pre-clinical animal studies and is preparing for human clinical trials for its core technology TargetTab™. This proprietary and patented wireless capsule will revolutionize targeted drug delivery and medicine adherence.
DENVER, CO — Prescription pills are often delivered to the wrong site, at wrong times, and without feedback, resulting in ineffective treatments, wasted medication, and high toxicity. The remote-controlled TargetTab™ is poised to change these shortcomings and revolutionize the healthcare industry. Today, there is no wireless powered and controlled ingestible electronic capsule drug delivery system on the market. SmartTab has been patented and just passed Pre-Clinical Animal studies and will be entering Human Clinical studies in the coming months.
Product Overview
- Ingestible, wireless, remote-controlled and powered drug delivery as a capsule
- Swallowed by patient, traveling through gastrointestinal tract
- Releases therapeutics at the right place at the right time
- Relays real-time data to doctors, apps, and mobile devices
With 72% of all prescription drugs’ consumption not compliant and $285 billion lost annually due to patient non-compliances, SmartTab is destined to make a profound impact on healthcare delivery. Patient benefits include decreased healthcare costs, specific body site delivery, OnDemand delivery timing, increased drug compliance, real-time monitoring, integration with Internet of Medical Things (IoMT).
Early Success
- 2017- First patent issued
- 2018- Proven actuation/release utilizing wireless power and communication system, FDA-USP Dissolution testing successful
- 2019- Pre-Clinical Animal studies successful
Customer comments
No comments were found for SmartTab Completes Successful Preclinical Animal Studies for TargetTab™ Platform. Be the first to comment!